Bioventus (BVS) Price to Sales (2021 - 2026)

Bioventus (BVS) has reported Price to Sales for 6 consecutive years, with 5.36 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 41.46% year-over-year to 5.36; the trailing twelve-month figure through Jun 2026 stood at 1.41 (up 42.31% YoY), and the FY2025 full-year result was 1.09, down 27.32% from the prior year.
• Price to Sales declined to 5.36 in Q2 2026 per BVS's latest filing, from 5.65 in the prior quarter.
• Across five years, Price to Sales topped out at 8.96 in Q2 2022 and bottomed at 0.7 in Q2 2023.
• Historically, Price to Sales has averaged 4.09 across 5 years, with a median of 3.91 in 2022.
• The sharpest annual moves came in 2023 and 2024: Price to Sales tumbled 92.15% in 2023, then surged 354.48% in 2024.
• Over 5 years, Price to Sales stood at 1.61 in 2022, then surged by 90.52% to 3.08 in 2023, then surged by 81.15% to 5.57 in 2024, then declined by 29.92% to 3.91 in 2025, then soared by 37.3% to 5.36 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 5.36, 5.65, and 3.91 for Q2 2026, Q1 2026, and Q4 2025 respectively.